Masoon Darou, Biotechnological Drugs and Vaccines Producer
The First Iranian Botox Manufacturer
The mission of Masoon Darou
Our expertise
Our work principles
The mission of Masoon Darou
The mission of Masoon Darou Complex is to train, streamline and utilize skilled human resources, design and create production and laboratory spaces in accordance with the latest GMP, GLP and biosafety standards, conduct and conduct applied research to improve community health, and promote researcher communication at the national and international levels.
The vision of Masoon Darou Complex is to strive to produce all new generation immunopharmacological products needed by the country at the level of World Health Organization standards.
Performing all tasks at the highest possible level, creating a suitable motivational environment for all employees to produce high quality products and improve people’s health indicators, preserving human dignity and values, strengthening the professional skills of employees and creating a culture of innovation, and optimally using national resources are considered to be the core values of the complex.
Our expertise
Masoon Daru Knowledge-Based Company is trying to produce biotechnological drugs with new technologies by recruiting specialized and efficient personnel.
Masoon Daru Company is the first and only manufacturer of various types of monovalent and polyvalent Clostridium botulinum antitoxin, Haemophilus influenzae type b vaccine with the trade name MAS-HibVAC® , and Clostridium botulinum toxin type A with the trade name Masport® in the country.
Our work principles
About Masoon Darou
Masoon Darou Pharmaceutical Company (Private Joint Stock Company) started its activities in 2007 as a knowledge-based company by acquiring technical knowledge and producing biotechnological drugs and vaccines for human consumption and providing new drugs with complex technologies in order to fight diseases and improve the health of the community.
In 2012, this company won first place in the category of technologists at the 8th Sheikh Bahai National Technology Festival.
This knowledge-based company, by attracting specialized and efficient personnel, is trying to produce biotechnological drugs with new technologies.
Masoon Darou Company is the first and only manufacturer of various types of monovalent and polyvalent Clostridium botulinum antitoxin with the trade name ZABOTRIX®, Haemophilus influenzae type b vaccine with the trade name MAS-HibVAC® and Clostridium botulinum toxin type A with the trade name MASPORT® in the country.
These products are produced at Masoon Darou Company with a quality at the level of American and European standards. The production capacities created in this company are several times the country’s needs, and currently this company is able to fully meet domestic consumption needs.
CEO's message
Health is humanity’s most fundamental and invaluable asset—an asset whose preservation requires a profound commitment to scientific excellence, innovation, and responsibility. In an era of rapid advancements in biomedical science, addressing complex and life-threatening diseases demands precise, patient-centered approaches grounded in a deep understanding of the molecular and cellular mechanisms of life.
At Masoon Darou Pharmaceutical Company, our core mission is centered on the development and manufacturing of advanced biologic medicines through the application of cutting-edge biotechnology platforms. These innovative technologies enable the design and delivery of targeted, safe, and effective therapeutic solutions that address unmet medical needs and improve patient outcomes.
Driven by rigorous scientific research, stringent quality standards, and advanced technological infrastructure, we continuously strive to elevate therapeutic excellence and contribute to better clinical outcomes.
Quality, safety, and efficacy are not merely performance indicators; they are the fundamental principles that guide every stage of research, development, and manufacturing at Masoon Darou. Every scientific achievement we attain reflects our unwavering commitment to the medical community and to patients worldwide, representing a meaningful step toward building a healthier future for all.
Dr. Ehsan Aali
CEO
Masoon Darou Products
News and Events
Dubai Derma
8-10 sep 2026
READ MORE
Khorasan Dermatology Congress
10 sep 2025
READ MORE
IRAN EXPO
3 May 2025
READ MORE
Dubai Derma
14-16 April 2025
READ MORE
Shiraz Skin Congress
11 Jun 2025
READ MORE
Global Partners
Trusted partnerships across international markets, delivering excellence in biopharmaceutical innovation and aesthetic medicine.
honor to collaborate with the best
